UNSPSC 51144304: Phenmetrazine

This classification denotes a cns stimulant and anorexiant with the molecular formula C11H15NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) XA501VL3VR, chemically known as 3-methyl-2-phenyltetrahydro-2h-1,4-oxazine but more generally known as phenmetrazine, which bears US NIH Compound Identifier 4762. European Medicines Agency schedules Phenmetrazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09769MIG.

UNSPSC 51144304 Phenmetrazine, a Commodity code, does not map clearly to the recent state and local opportunities tagged under it. The source shows no solicitations for phenmetrazine specifically; instead, recent opportunities address naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical supply contracts — none of which involve phenmetrazine or controlled-substance stimulants. The mismatch suggests either a tagging error in the underlying procurement data or a code classification that does not reflect current buying patterns under this Commodity designation. Issuing bodies in the source include a county health department (Seminole County, Florida), a state health and human services commission (Texas HHS), and a multistate cooperative purchasing alliance (MMCAP, Minnesota Department of Administration) — representing a mix of local, state, and inter-jurisdictional procurement entities focused on pharmaceutical supply and pharmacy benefit management rather than on the active pharmaceutical ingredient or finished-dose formulation that the code nominally describes.

Recent activity centers on Seminole County's IFB for naloxone and drug deactivation systems (posted June 30, 2026, response deadline July 26, 2026), Texas HHS's Request for Information on direct-to-manufacturer prescription programs (posted April 3, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and over-the-counter products across multiple states including Oregon (posted January 20, 2026, proposals due March 26, 2026). These opportunities span Florida, Texas, Minnesota, and Oregon, reflecting geographic distribution across the South, Southwest, and Upper Midwest. The code shows little relevant recent activity under its stated scope, and business development professionals should verify the correct UNSPSC classification for phenmetrazine before committing resources to pursuit.